EYE ALLERGY: Edited by Leonard Bielory and Abraham SolomonOcular allergic contact dermatitis from topical drugsErdinest, Nira; Nche, Eleanora; London, Naomib; Solomon, AbrahamaAuthor Information aDepartment of Ophthalmology, Hadassah-Hebrew University Medical Center bPrivate Practice, Jerusalem, Israel Correspondence to Abraham Solomon, MD, Department of Ophthalmology, Cornea & Refractive Surgery Service, Hadassah-Hebrew University Medical Center, Jerusalem, Israel 91120. Tel: +972 507874664; e-mail: firstname.lastname@example.org Current Opinion in Allergy and Clinical Immunology: October 2020 - Volume 20 - Issue 5 - p 528-538 doi: 10.1097/ACI.0000000000000677 Buy Metrics Abstract Purpose of review Ocular allergic contact dermatitis is a common yet challenging and frequently misdiagnosed condition. Inappropriate or delayed treatment can contribute to a variety of clinical symptoms such as tearing and itching with signs such as ptosis and cicatricial ectropion, resulting in deterioration of disease, for which the topical medication was originally prescribed to resolve. Recent findings Understanding previously unrecognized pathogenic mechanisms involving ocular contact dermatitis has driven new approaches to control the inflammatory process by neutralizing inflammatory mediators and their receptors. Summary Early diagnosis and removing the antagonizing substance is crucial to manage ocular contact dermatitis. Steroid therapy is usually required to reduce symptoms. As ocular allergic dermatitis often develops in patients using drugs for chronic conditions that necessitate chronic application, it may be difficult at times to discontinue or replace the offending agent. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.